

Paolo Magni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6669326/publications.pdf>

Version: 2024-02-01

109
papers

2,554
citations

257101

24
h-index

223531

46
g-index

115
all docs

115
docs citations

115
times ranked

2715
citing authors

#	ARTICLE	IF	CITATIONS
1	A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 117-128.	1.1	4
2	A machine learning approach based on ACMG/AMP guidelines for genomic variant classification and prioritization. <i>Scientific Reports</i> , 2022, 12, 2517.	1.6	26
3	Characterisation of individual ferritin response in patients receiving chelation therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3683-3694.	1.1	4
4	In Vitro–In Vivo Correlation (IVIVC) Population Modeling for the In Silico Bioequivalence of a Long-Acting Release Formulation of Progesterone. <i>Pharmaceutics</i> , 2021, 13, 255.	2.0	6
5	dCas9 regulator to neutralize competition in CRISPRi circuits. <i>Nature Communications</i> , 2021, 12, 1692.	5.8	22
6	Functional genomics meta-analysis to identify gene set enrichment networks in cardiac hypertrophy. <i>Biological Chemistry</i> , 2021, 402, 953-972.	1.2	3
7	A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1605-1619.	1.6	2
8	Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1365-1390.	2.5	7
9	Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules. <i>Pharmaceutics</i> , 2021, 13, 1101.	2.0	12
10	A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies. <i>Oncotarget</i> , 2021, 12, 1434-1441.	0.8	7
11	Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1396-1411.	1.3	7
12	CRISPR Interference Modules as Low-Burden Logic Inverters in Synthetic Circuits. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 743950.	2.0	2
13	Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2 ^{â€™} ,2 ^{â€™} -difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 608-617.	1.5	2
14	Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 150, 105359.	1.9	3
15	Engineering endogenous fermentative routes in ethanologenic <i>Escherichia coli</i> W for bioethanol production from concentrated whey permeate. <i>New Biotechnology</i> , 2020, 57, 55-66.	2.4	9
16	A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance. <i>Cancer Research</i> , 2020, 80, 820-831.	0.4	10
17	Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds. <i>AAPS Journal</i> , 2020, 22, 116.	2.2	6
18	Integration of enzymatic data in <i>Bacillus subtilis</i> genome-scale metabolic model improves phenotype predictions and enables in silico design of poly- ¹³ -glutamic acid production strains. <i>Microbial Cell Factories</i> , 2019, 18, 3.	1.9	56

#	ARTICLE	IF	CITATIONS
19	Comprehensive kinome NGS targeted expression profiling by KING-REX. <i>BMC Genomics</i> , 2019, 20, 307.	1.2	1
20	Use of prior knowledge and extrapolation in paediatric drug development: A case study with deferasirox. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104931.	1.9	4
21	Mechanistic Models of Inducible Synthetic Circuits for Joint Description of DNA Copy Number, Regulatory Protein Level, and Cell Load. <i>Processes</i> , 2019, 7, 119.	1.3	5
22	Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 137-154.	0.8	16
23	Building in-house PBPK modelling tools for oral drug administration from literature information. <i>ADMET and DMPK</i> , 2019, 7, 4-21.	1.1	8
24	A Bioinformatics Approach to Explore MicroRNAs as Tools to Bridge Pathways Between Plants and Animals. Is DNA Damage Response (DDR) a Potential Target Process?. <i>Frontiers in Plant Science</i> , 2019, 10, 1535.	1.7	9
25	Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 27-42.	0.8	10
26	A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats. <i>Pharmaceutical Research</i> , 2019, 36, 38.	1.7	10
27	Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach. <i>Journal of Theoretical Biology</i> , 2018, 450, 1-14.	0.8	9
28	Complex Bayesian Modeling Workflows Encoding and Execution Made Easy With a Novel WinBUGS Plugin of the Drug Disease Model Resources Interoperability Framework. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 298-308.	1.3	3
29	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 5-21.	2.5	7
30	A synthetic close-loop controller circuit for the regulation of an extracellular molecule by engineered bacteria. <i>IEEE Transactions on Biomedical Circuits and Systems</i> , 2018, 13, 1-1.	2.7	7
31	Current mathematical models for cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-15.	2.5	15
32	Model Description Language (MDL): A Standard for Modeling and Simulation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 647-650.	1.3	15
33	Fermentation of lactose to ethanol in cheese whey permeate and concentrated permeate by engineered <i>Escherichia coli</i> . <i>BMC Biotechnology</i> , 2017, 17, 48.	1.7	42
34	Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 97, 70-78.	1.9	16
35	Re-using biological devices: a model-aided analysis of interconnected transcriptional cascades designed from the bottom-up. <i>Journal of Biological Engineering</i> , 2017, 11, 50.	2.0	10
36	Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice. <i>AAPS Journal</i> , 2016, 18, 1233-1243.	2.2	9

#	ARTICLE	IF	CITATIONS
37	Analysis of amplicon-based NGS data from neurological disease gene panels: a new method for allele drop-out management. BMC Bioinformatics, 2016, 17, 339.	1.2	12
38	Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. Diabetes Care, 2016, 39, 1151-1160.	4.3	98
39	Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. Pharmaceutical Research, 2016, 33, 1657-1670.	1.7	7
40	Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 402-410.	1.3	9
41	Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 305-312.	1.3	6
42	A BioBrick-compatible Vector for Allelic Replacement Using the Xyle Gene as Selection Marker. Biological Procedures Online, 2016, 18, 6.	1.4	3
43	Experimental measurements and mathematical modeling of biological noise arising from transcriptional and translational regulation of basic synthetic gene circuits. Journal of Theoretical Biology, 2016, 395, 153-160.	0.8	11
44	Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 316-319.	1.3	37
45	Modelling the effects of cell-to-cell variability on the output of interconnected gene networks in bacterial populations. BMC Systems Biology, 2015, 9, S6.	3.0	5
46	PhosphoHunter: An Efficient Software Tool for Phosphopeptide Identification. Advances in Bioinformatics, 2015, 2015, 1-12.	5.7	6
47	Methods for genetic optimization of biocatalysts for biofuel production from dairy waste through synthetic biology. , 2015, 2015, 953-6.		2
48	2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes and Endocrinology, 2015, 3, 939-947.	5.5	189
49	Quantification of the gene silencing performances of rationally-designed synthetic small RNAs. Systems and Synthetic Biology, 2015, 9, 107-123.	1.0	8
50	Multi-Faceted Characterization of a Novel LuxR-Repressible Promoter Library for Escherichia coli. PLoS ONE, 2015, 10, e0126264.	1.1	19
51	Population Modelling. , 2014, , 131-158.		2
52	Tumor Growth Modelling for Drug Development. , 2014, , 449-477.		0
53	Modelling for Synthetic Biology. , 2014, , 545-564.		3
54	Online Microreactor Titanium Dioxide RPLC-LTQ-Orbitrap MS Automated Platform for Shotgun Analysis of (Phospho) Proteins in Human Amniotic Fluid. Chromatographia, 2014, 77, 39-50.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Mathematical modeling of growth and death dynamics of mouse embryonic stem cells irradiated with \hat{I}^3 -rays. <i>Journal of Theoretical Biology</i> , 2014, 363, 374-380.	0.8	2
56	Half-life measurements of chemical inducers for recombinant gene expression. <i>Journal of Biological Engineering</i> , 2014, 8, 5.	2.0	30
57	A Review of Mixed-effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-10.	1.3	137
58	A standard vector for the chromosomal integration and characterization of BioBrick parts in <i>Escherichia coli</i> . <i>Journal of Biological Engineering</i> , 2013, 7, 12.	2.0	28
59	A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 471-482.	1.1	32
60	Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1147-1157.	1.1	30
61	Modeling of human tumor xenografts and dose rationale in oncology. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e365-e372.	4.0	36
62	Characterization of an inducible promoter in different DNA copy number conditions. <i>BMC Bioinformatics</i> , 2012, 13, S11.	1.2	26
63	TGI-Simulator: A visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug. <i>Computer Methods and Programs in Biomedicine</i> , 2012, 105, 162-174.	2.6	7
64	A Minimal Model of Tumor Growth Inhibition in Combination Regimens Under the Hypothesis of No Interaction Between Drugs. <i>IEEE Transactions on Biomedical Engineering</i> , 2012, 59, 2161-2170.	2.5	7
65	Mouse embryonic stem cells that survive \hat{I}^3 -rays exposure maintain pluripotent differentiation potential and genome stability. <i>Journal of Cellular Physiology</i> , 2012, 227, 1242-1249.	2.0	24
66	Bottom-Up Engineering of Biological Systems through Standard Bricks: A Modularity Study on Basic Parts and Devices. <i>PLoS ONE</i> , 2012, 7, e39407.	1.1	29
67	Summarizing Probe Intensities of Affymetrix GeneChip 3' Expression Arrays Taking into Account Day-to-Day Variability. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2011, 8, 1425-1430.	1.9	1
68	Multiplexing and demultiplexing logic functions for computing signal processing tasks in synthetic biology. <i>Biotechnology Journal</i> , 2011, 6, 784-795.	1.8	28
69	Characterization of a synthetic bacterial self-destruction device for programmed cell death and for recombinant proteins release. <i>Journal of Biological Engineering</i> , 2011, 5, 8.	2.0	26
70	Accurate peak list extraction from proteomic mass spectra for identification and profiling studies. <i>BMC Bioinformatics</i> , 2010, 11, 518.	1.2	10
71	A Perl procedure for protein identification by Peptide Mass Fingerprinting. <i>BMC Bioinformatics</i> , 2009, 10, S11.	1.2	6
72	A model-based approach to the in vitro evaluation of anticancer activity. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 827-836.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Testing additivity of anticancer agents in pre-clinical studies: A PK/PD modelling approach. <i>European Journal of Cancer</i> , 2009, 45, 3336-3346.	1.3	32
74	A Minimal Model of Tumor Growth Inhibition. <i>IEEE Transactions on Biomedical Engineering</i> , 2008, 55, 2683-2690.	2.5	26
75	TimeClust: a clustering tool for gene expression time series. <i>Bioinformatics</i> , 2008, 24, 430-432.	1.8	50
76	Determining the maximum periodic inspection interval for medium voltage motors using a Markov model. <i>Production Planning and Control</i> , 2008, 19, 356-364.	5.8	6
77	A procedure to decompose high resolution mass spectra. <i>BMC Bioinformatics</i> , 2007, 8, .	1.2	5
78	Inferring gene regulatory networks by integrating static and dynamic data. <i>International Journal of Medical Informatics</i> , 2007, 76, S462-S475.	1.6	7
79	Precedence Temporal Networks to represent temporal relationships in gene expression data. <i>Journal of Biomedical Informatics</i> , 2007, 40, 761-774.	2.5	12
80	Reduced sampling schedule for the glucose minimal model: importance of Bayesian estimation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E177-E184.	1.8	14
81	A mathematical model to study the effects of drugs administration on tumor growth dynamics. <i>Mathematical Biosciences</i> , 2006, 200, 127-151.	0.9	74
82	A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays. <i>BMC Bioinformatics</i> , 2006, 7, 514.	1.2	54
83	A minimal model describing the effect of drug administration on tumor growth dynamics. , 2006, , .		2
84	Inferring gene expression networks via static and dynamic data integration. <i>Studies in Health Technology and Informatics</i> , 2006, 124, 119-24.	0.2	3
85	TA-clustering: Cluster analysis of gene expression profiles through Temporal Abstractions. <i>International Journal of Medical Informatics</i> , 2005, 74, 505-517.	1.6	22
86	Temporal data mining for the quality assessment of hemodialysis services. <i>Artificial Intelligence in Medicine</i> , 2005, 34, 25-39.	3.8	93
87	Random Walk Models for Bayesian Clustering of Gene Expression Profiles. <i>Applied Bioinformatics</i> , 2005, 4, 263-276.	1.7	14
88	Learning Rules with Complex Temporal Patterns in Biomedical Domains. <i>Lecture Notes in Computer Science</i> , 2005, , 23-32.	1.0	8
89	Insulin Minimal Model Indexes and Secretion: Proper Handling of Uncertainty by a Bayesian Approach. <i>Annals of Biomedical Engineering</i> , 2004, 32, 1027-1037.	1.3	15
90	Analysing Italian voluntary abortion data using a Bayesian approach to the time series decomposition. <i>Statistics in Medicine</i> , 2004, 23, 105-123.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents. <i>Cancer Research</i> , 2004, 64, 1094-1101.	0.4	432
92	Three Thiamine Analogues Differently Alter Thiamine Transport and Metabolism in Nervous Tissue: An In Vivo Kinetic Study Using Rats. <i>Metabolic Brain Disease</i> , 2003, 18, 245-263.	1.4	22
93	In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 507-513.	1.1	9
94	Integrating model-based decision support in a multi-modal reasoning system for managing type 1 diabetic patients. <i>Artificial Intelligence in Medicine</i> , 2003, 29, 131-151.	3.8	56
95	Quality Assessment of Hemodialysis Services through Temporal Data Mining. <i>Lecture Notes in Computer Science</i> , 2003, , 11-20.	1.0	5
96	Minimal model $S_{I_I}=0$ problem in NIDDM subjects: nonzero Bayesian estimates with credible confidence intervals. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 282, E564-E573.	1.8	42
97	Nonparametric AUC estimation in population studies with incomplete sampling: a Bayesian approach. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 445-471.	0.8	23
98	Compartmental model identification based on an empirical Bayesian approach: The case of thiamine kinetics in rats. <i>Medical and Biological Engineering and Computing</i> , 2001, 39, 700-706.	1.6	9
99	A Bayesian Nonparametric Approach to AUC Determination in Population Studies. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2000, 33, 249-254.	0.4	0
100	Deciding when to intervene: a Markov decision process approach. <i>International Journal of Medical Informatics</i> , 2000, 60, 237-253.	1.6	40
101	Intelligent analysis of clinical time series: an application in the diabetes mellitus domain. <i>Artificial Intelligence in Medicine</i> , 2000, 20, 37-57.	3.8	63
102	Bayesian Identification of a Population Compartmental Model of C-Peptide Kinetics. <i>Annals of Biomedical Engineering</i> , 2000, 28, 812-823.	1.3	13
103	Bayesian analysis of blood glucose time series from diabetes home monitoring. <i>IEEE Transactions on Biomedical Engineering</i> , 2000, 47, 971-975.	2.5	23
104	Intelligent Analysis of Clinical Time Series by Combining Structural Filtering and Temporal Abstractions. <i>Lecture Notes in Computer Science</i> , 1999, , 261-270.	1.0	4
105	Bayesian function learning using MCMC methods. <i>IEEE Transactions on Pattern Analysis and Machine Intelligence</i> , 1998, 20, 1319-1331.	9.7	50
106	A new approach to optimal dynamic therapy planning. <i>Proceedings</i> , 1998, , 936-40.	0.6	1
107	Dynamic Probabilistic Networks for Modelling and Identifying Dynamic Systems: A MCMC Approach. <i>Intelligent Data Analysis</i> , 1997, 1, 245-262.	0.4	9
108	DT-Planner: an environment for managing dynamic decision problems. <i>Computer Methods and Programs in Biomedicine</i> , 1997, 54, 183-200.	2.6	12

#	ARTICLE	IF	CITATIONS
109	Dynamic probabilistic networks for modelling and identifying dynamic systems: a MCMC approach. Intelligent Data Analysis, 1997, 1, 245-262.	0.4	7